|
|
Clinical Questions in Cardiology: Using Glucagon-like Peptite-1 Receptor Agonists
The glucagon-like peptide-1 receptor agonist (GLP-1RA) class of medications has become an important option for treating patients with type 2 diabetes mellitus (T2D). Cardiovascular outcome trials also show that selected GLP-1RAs exert beneficial cardiovascular benefits in patients with and without T2D. In this activity, case studies commonly encountered in cardiology practice are utilized to prompt reflection on opportunities for reducing cardiovascular risk. Drawing on seminal research and th... |
|
|
Managing Obesity in Adolescent Patients Your Top 10 Questions Answered
The rate of obesity in children and adolescents is increasing, posing significant physical and mental health challenges through childhood and adolescence and into adulthood. Recently, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been approved for use in patients as young as 12 years, and it is critical that clinicians initiate both lifestyle management and pharmacologic therapies as early as possible. Dr. Fatima Stanford discusses 10 common questions asked about managing obesity ... |
|
|
WEBINAR: Legal Insights into Peptide & Semaglutide Compounding: Navigating FDA, State Boards, and Telemedicine
Compounding peptides and semaglutide comes with unique legal challenges and opportunities. This webinar will break down the latest updates on regulations and provide practical guidance for compounders.
In this 1-hour CE session, our speakers will cover the FDA’s current stance on peptide compounding, key updates from state Boards of Pharmacy, legal considerations with brand manufacturers, the role of telemedicine in compounding, and tips for handling bulk chemical ingredients. |
|